LL-37

Unverified protocol notes

Protocol logic check

Independent evidence

Regulatory status: unapproved or compounded peptide with FDA safety risk flag

Storage

No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.

Contraindications (limited evidence)

• Active autoimmune disease: LL-37 is a potent immunological alarm signal that activates multiple innate immune pathways simultaneously (TLR-4, FPRL1, mast cell degranulation, neutrophil chemotaxis); in subjects with active autoimmune conditions, this immune activation can trigger severe flares by amplifying the already-dysregulated immune response against self-tissue. Limited / unverified
• Systemic lupus erythematosus (SLE): LL-37 has been specifically implicated in SLE pathogenesis: endogenous LL-37 forms complexes with self-DNA that activate TLR-9 on plasmacytoid dendritic cells, driving the type-I interferon signature that characterizes SLE; exogenous LL-37 administration in SLE subjects could dramatically worsen disease activity. Limited / unverified
• Psoriasis (active, severe): LL-37 is a primary initiator of psoriatic inflammation; it forms complexes with self-DNA in psoriatic skin lesions that activate the pDC/TLR-7/9 pathway driving IL-23/IL-17 pathological cascade; LL-37 administration in psoriatic subjects may severely worsen plaques. Limited / unverified
• Rheumatoid arthritis (active disease): cathelicidin-mediated immune activation in inflamed joints could precipitate acute synovitis flares. Limited / unverified
• Organ transplant recipients: immune activation from LL-37 in immunosuppressed transplant recipients may provoke rejection episodes. Limited / unverified
• Concurrent anticoagulant therapy: LL-37 activates mast cells and platelets; theoretical interaction with anticoagulation warrants monitoring. Limited / unverified
• Known hypersensitivity to LL-37, cathelicidin-derived peptides, or formulation excipients. Limited / unverified
• Subjects with a very high established pathogen burden without clinical supervision: the Herxheimer reaction at LL-37 initiation in subjects with severe Lyme, MRSA, or fungal burdens can be medically dangerous; clinical oversight and KPV availability for Herxheimer management is strongly advisable. Limited / unverified
• Pregnancy: immune activation and cytokine release from LL-37 carry risk in pregnancy; not established as safe. Limited / unverified
• Breastfeeding: no safety data. Limited / unverified
• Active inflammatory bowel disease (Crohn's, UC) in severe flare: gut epithelial LL-37 dysregulation is already implicated in IBD pathogenesis; systemic exogenous LL-37 during active flare could worsen mucosal inflammation. Limited / unverified

Side effects (limited evidence)

• Jarisch-Herxheimer Reaction (JHR): the primary, defining, and most clinically significant adverse effect of LL-37 when used for chronic infection; characterized by sudden onset of fever (often 38-40°C), severe chills, intense fatigue, diaphoresis, myalgia, arthralgia, and headache occurring within hours of the first few doses; caused by mass simultaneous pathogen killing releasing endotoxins and microbial antigens faster than the immune system can clear them; severity is proportional to pathogen burden and is the reason for mandatory slow dose escalation. Limited / unverified
• Intense injection site welts and induration: a consistent and dose-dependent adverse effect; LL-37's cationic amphipathic structure interacts with subcutaneous tissue and activates local mast cells, producing significant local inflammatory welts that can be painful, warm, and raised; more pronounced than virtually any other peptide in this database; site rotation and starting at 50mcg are the primary management strategies. Limited / unverified
• Severe joint pain (arthralgia): part of the Herxheimer reaction cascade; may be extreme in Lyme disease subjects as spirochete die-off in joint tissue releases inflammatory mediators. Limited / unverified
• Profound fatigue: the systemic inflammatory response from Herxheimer reactions consumes significant metabolic resources; profound fatigue lasting 24-72 hours per episode is expected, particularly in early titration. Limited / unverified
• Fever: Herxheimer reaction fever can reach 39-40°C and be alarming; it is a sign the LL-37 is working but should be monitored; subjects must be able to distinguish Herxheimer fever from infection-worsening fever. Limited / unverified
• Chills and rigors: accompanies Herxheimer fever; can be intense; warm blankets, hydration, and rest are the management. Limited / unverified
• Headache: common during Herxheimer reactions; related to systemic cytokine release (TNF-α, IL-6, IL-1β). Limited / unverified
• Autoimmune flare triggering: in subjects with undiagnosed or quiescent autoimmune conditions; LL-37's TLR-9 activation and DNA-complex formation can unmask or worsen autoimmune pathology. Limited / unverified
• Nausea and gastrointestinal disturbance: less common; part of the systemic inflammatory response during Herxheimer events. Limited / unverified
• Pro-angiogenic activity: LL-37 stimulates VEGFR2-mediated angiogenesis; in the context of active malignancy this is a theoretical oncological concern; in wound healing contexts it is a therapeutic benefit. Limited / unverified
• Potential mast cell activation syndrome (MCAS) exacerbation: subjects with underlying MCAS may experience severe reactions even at low doses due to LL-37's direct mast cell degranulation activity. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

None listed.

Sources

• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3